The ability of metamizol to inhibit cyclooxygenase-1 and cyclooxygenase-2 activities has been evaluated using different cyclooxygenase sources. Metamizol inhibited purified cyclooxygenase-1 and cyclooxygenase-2 with an IC of about 150 mgrml. A similar IC 50 50
Introduction
The rate limiting step in the synthesis of prostaglandins and thromboxanes is the conversion of arachidonate to prostaglandin H , which is catalyzed by two isozymes 2 Ž cyclooxygenase-1 and cyclooxygenase-2 for a review, see . Smith et al., 1998 and . The first isozyme, cyclooxygenase-1, is a constitutive enzyme ex-Ž pressed in many tissues and also in platelets Funk et al., . 1991; Simmons et al., 1991 . Cyclooxygenase-1 has been involved in ''housekeeping'' functions, such as coordinating the actions of circulating hormones, mucose gastric Ž protection and regulating vascular homeostasis Smith et . al., 1989 . In contrast, cyclooxygenase-2 is an inducible enzyme and is primarily associated with inflammation. Cyclooxygenase-2 is induced in a variety of cell types by diverse stimuli including cytokines, growth factors, mito-Ž gens and tumour promoters Kujubu et al., 1991; Lee et al., 1992; DeWitt and Meade, 1993; Ristimaki et al., 1994;  . Coffey et al., 1997 . In brain and spinal cord cyclooxy-Ž genase-2 is constitutively expressed McCormak, 1994; . Cashman, 1996; Yaksh et al., 1998 . Cyclooxygenase-1 and cyclooxygenase-2 are encoded Ž by different genes Yokoyama and Tanabe, 1989; Kraemer . et al., 1992 but they exhibit a 62% homology at the aminoacid level. The three-dimensional structures of both Ž enzymes have been solved by X-ray crystallography Picot . et al., 1994; Kurumbail et al., 1996 , and all the residues that make up the cyclooxygenase active site have been shown to be identical except for the amino acid at position 523, which is an isoleucine in cyclooxygenase-1 but a valine in cyclooxygenase-2. This residue is found at the bottom of a hydrophobic channel where nonsteroidal anti- 
Ž . inflammatory drugs NSAIDs bind. A mutant of cyclooxygenase-2 in which valine
523 is exchanged for isoleucine shows inhibitor binding and selectivity profiles comparable Ž to those of wild-type cyclooxygenase-1 Gierse et al., . 1996; Guo et al., 1996 . Metamizol is a prodrug which, at room temperature and in an atmosphere with oxygen, is spontaneously, nonenzy-Ž matically converted to 4-methylaminoantipyrine Levy, . 1986; Levy et al., 1995 . Subsequently, the N-methyl side chain of 4-methylaminoantipyrine is oxidized to yield 4-formylaminoantipyrine, which is further converted to 4-aminoantipyrine. Therefore, it is accepted that metamizol in aqueous solution and in the presence of oxygen consists Ž of a group of several pyrazolone derivatives Brodgen, . 1986; Levy, 1986; Levy et al., 1995 , of which 4-methylaminoantipyrine is pharmacologically the most important ŽBrodgen, 1986; Levy, 1986; Levy et al., 1995; Vlahov et . al., 1990 . In the present paper hereafter, the term metamizol will encompass this whole set of pyrazolone deriva-Ž . tives Fig. 1A , all of which have analgesic, antipyretic, and relatively weak antiinflammatory properties.
It has been proposed that the antinociceptive action of Ž metamizol is at least partially centrally mediated Carlsson et al., 1986; Gelgor et al., 1992; Tortorici and Vanegas, . 1995 , even though an association of metamizol with Ž opioid receptors is unlikely Beirith et al., 1998; Taylor et . al., 1998 . On the other hand, a dissociation between the antiinflammatory and analgesic effects of metamizol, and inhibition of prostaglandins synthesis was reported prior to Ž the discovery of cyclooxygenase-2 Dembinska- Kiec et al., 1976; Brune, 1983; Eldor et al., 1984; Lorenzetti and . Ferreira, 1985 .
The importance of the discovery of the inducible form of cyclooxygenase is highlighted by the differences in pharmacology between the two isozymes. The antiinflammatory capacity of the different NSAIDs is now proposed to be associated with the capacity of inhibiting cyclooxygenase-2 activity. A central analgesic effect of NSAIDs Ž has also been proposed McCormak, 1994; Cashman, 1996; . Yaksh et al., 1998 , which is probably mediated by regula-Ž tion of cyclooxygenase-2 activity in the spinal cord Dirig . et al., 1997; Smith et al., 1998 . Regulation of cyclooxygenase-1 activity, on the other hand, is thought to be responsible for the gastric and renal side effects of NSAIDs, Ž as well as for their antithrombotic activity for a review, . see Pairet and Engelhardt, 1996; . Cyclooxygenase-2 is presently regarded as an important target for the development of novel NSAIDs with improved toxicological profiles.
In this paper we evaluate the capacity of metamizol to inhibit cyclooxygenase-1 and cyclooxygenase-2 activities using different cell systems, as well as purified cyclooxy-Ž . Fig. 1 . Binding mode of 4-methylaminoantipyrine in the active site of cyclooxygenase-2. Above Chemical formulae of metamizol and its active Ž . Ž . Ž . derivatives. Right page Molscript representation Kraulis, 1991 of 4-methylaminoantipyrine thicker bonds docked in the active site of human cyclooxygenase-2, as proposed by programs GRID and AutoDock. In this orientation the interactions between the inhibitor and the enzyme are optimized. Ž Relevant residues are shown as ball-and-stick and have been labeled the numbering scheme follows the convention for the sheep cyclooxygenase-1 . structure . This binding mode is identical to that found in the 4-methylaminoantipyrine-cyclooxygenase-1 complex and is presumed to be the same for the active derivatives shown in A. genase-1 and cyclooxygenase-2. We also present a molecular model of the interaction between 4-methylaminoantipyrine, the pharmacologically most important derivative of metamizol, and the cyclooxygenase active sites of both cyclooxygenase-1 and cyclooxygenase-2.
Material and methods

Docking of 4-methyl-amino-antipyrine into the cyclooxygenase actiÕe sites of human cyclooxygenase-1 and cyclooxygenase-2
The experimentally determined three-dimensional struc-Ž . tures of ovine cyclooxygenase-1 Picot et al., 1994 and Ž . mouse cyclooxygenase-2 Kurumbail et al., 1996 , together with our homology-based models of their human counter-Ž . parts Garcıa-Nieto et al., 1999 , were studied. Two possible conformers of 4-methylaminoantipyrine were initially considered differing in the orientation of the N-methyl substituent relative to the plane of the pyrazole ring, and their geometries were optimized by using the semiempiri-Ž . cal molecular orbital AM1 method Dewar et al., 1985 . Atom-centered charges were then derived by fitting the calculated molecular electrostatic potential to a mono-Ž . pole-monopole expression Besler et al., 1990 . Then, the Monte Carlo simulated annealing technique implemented Ž . in AutoDock Morris et al., 1996 was used to generate different conformations and orientations of 4-methylaminoantipyrine within the enzyme binding sites and to evaluate the energy of each configuration. In addition, the active sites of these enzymes were probed for regions of steric and electrostatic complementarity with the functional Ž groups present in 4-methylaminoantipyrine i.e., aliphatic and aromatic carbons, carbonyl oxygen, and amino and . Ž heterocyclic ring nitrogens using program GRID Good-. ford, 1985 . The 4-methylaminoantipyrine favoured by AutoDock was then used as a rigid ligand for the GROUP Ž . module of GRID version 16, Molecular Discovery, 1997 , which automatically produces the ligand orientation that best matches the calculated maps for the atom probes.
Measurement of purified cyclooxygenase actiÕities
Purified cyclooxygenase-1 and cyclooxygenase-2 were Ž . obtained from Cayman Chemicals Ann Arbor, MI . Enw 14 x zyme activity was measured by conversion of C arachidonic acid to prostaglandins, after separation by thin layer Ž . Ž . chromatography TLC Mitchell et al., 1994 . The reaction was started by the addition of 10 units of the different enzymes to a reaction mixture made up to a final volume Ž of 1 ml, containing 50 mM Tris buffer pH 8, glutathione 5 . Ž . Ž .
5 mM , epinephrine 5 mM , hematin 1 mM , 1= 10 dpm w 14 x Ž . C arachidonic acid Amersham , 6.6 mM arachidonic ( )acid and different concentrations of metamizol. Samples were incubated in a shaking water bath at 378C for 10 min, after which the reaction was stopped by adding 30 ml of 1 mM HCl. One milliliter of saturated NaCl solution was added to each sample followed by 1.5 ml of ethylacetate. After mixing the samples by vortexing, they were centrifuged at 575 = g for 10 min and the ethyl acetate layer was transferred to a clean tube and dried under nitrogen stream. Prostaglandins were separated by TLC. Each sample was redissolved in 30 ml of chloroformrmethanol, 2:1 Ž . vrv , and 20 ml were applied onto a glass-backed silica Ž . gel plate Merck . The TLC plate was developed for approximately 90 min at room temperature in a solvent consisting of the upper phase of ethyl acetatertrimethyl Ž . pentaneracetic acidrwater, 110:50:20:100 vrv . For detection of the 14 C-labelled prostaglandins an autoradiography in an Instant Imager was performed.
Measurement of cyclooxygenase-1 actiÕity in intact cells
Ž . Bovine aortic endothelial cells BAEC , maintained in Ž . Dulbecco's Modified Eagle Medium DMEM with 10% fetal calf serum, 4 mM glutamine, 50 mgrml gentamicin at 378C, were incubated for 30 min with different concen-Ž . trations of metamizol 125-4000 mgrml or with indo-Ž . methacin 0.1-100 mgrml , after which arachidonic acid was added to a final concentration of 30 mM. Cells were incubated for further 15 min at 378C. The medium was Ž . then removed, and a radioimmunoassay kit Amersham was used to measure the formation of 6-keto-prostaglandin F . Metamizol did not interfere with the measurement of 1a 6-keto-prostaglandin F . Fresh human platelets were isolated as described by Ž . Font et al. 1992 . Acid-citrate-dextrose-anticoagulant blood samples were centrifuged at 180 = g for 10 min at 208C and the supernatant containing the platelets was Ž . Ž . diluted 1r1 vrv with phosphate saline buffer PBS . Cells were incubated with different concentrations of Ž . metamizol 125-4000 mgrml and stimulated with cal-Ž . cium ionophore A23187 0.25 mM . The levels of thromboxane B in the incubation media after 5 min of stimula- 
Measurement of cyclooxygenase-2 actiÕity in intact cells
Murine monocyte-macrophage J774A.1 cells, in RPMI 1640 medium supplemented with 10% fetal calf serum, Ž .Ž .
6 gentamicin 50 mgrml complete medium at 0.5 = 10 cellsrml, were treated with lipopolysaccharide at 1 mgrml for 12 h to induce cyclooxygenase-2. Complete medium was then changed and different concentrations of metamizol or indomethacin were added and the cells incubated for 30 min at 378C. The medium was then removed and prostaglandin E levels were analyzed by prostaglandin E 2 2 Ž . enzyme immunoassay system Amersham . Metamizol did not interfere with the measurement of prostaglandin E . 2 Human peripheral leukocytes from Buffy-Coat were Ž . separated using Histopaque 1099 Sigma as described by Ž . Tavares and Bennett 1993 and incubated for 2 h in complete medium at 0.5 = 10 6 cellsrml. Subsequently, the cells were incubated for 12 h with or without lipopoly-Ž . saccharide 3 mgrml , and in the presence or absence of different concentrations of metamizol. The prostaglandin E released to the incubation media was measured by 2 radioimmunoassay as described above.
Measurement of cyclooxygenase-2 actiÕity in macrophage cell extracts
Lipopolysaccharide at 1 mgrml was added for 12 h to confluent murine macrophages after which cells were washed and homogenized with a glass teflon homogenizer Ž . in 50 mM Tris buffer pH 7.4 containing 1 mM phenylmethyl sulfonyl fluoride, 50 mM pepstatin A, and 0.2 mM leupeptin. Broken cells were incubated at 378C in the presence of different concentrations of metamizol or indomethacin for 30 min. About 30 mM of arachidonic acid was then added, and the reaction continued for a further 15 min. The reaction was stopped by boiling, and after centrifugation at 10,000 = g for 30 min, prostaglandin E was 2 measured in the supernatant as described above. 
Results
Docking of 4-methylaminoantipyrine into the actiÕe sites of human cyclooxygenase-1 and cyclooxygenase-2
Both GRID and AutoDock found the same binding orientation for 4-methylaminoantipyrine, the main active derivative of metamizol, irrespective of the isozyme considered. The molecule binds at the bottom of the substrate channel placing the phenyl ring above the plane of Tyr 385 , the 4-amino group in close proximity to the hydroxyl of Tyr 355 , and the N 2 ring nitrogen facing the residue at Ž . position 523 Fig. 1B . The smaller size of the side chain of valine relative to that of isoleucine at this position allows the main substrate channel in cyclooxygenase-2 to extend into a side pocket that is not accessible to inhibitors in cyclooxygenase-1. 4-Methylaminoantipyrine does not appear to exploit this adjacent binding pocket, the occupancy of which is thought to be important for achieving Ž selectivity towards cyclooxygenase-2 Kurumbail et al., . 1996 , and a similar binding mode can be envisaged for the other derivatives shown in Fig. 1A. 
Inhibition of purified cyclooxygenase-1 and cyclooxygenase-2 by metamizol
Experiments to determine the activity of purified cyclooxygenase-1 and cyclooxygenase-2 in the presence of metamizol were carried out. Both enzymes were incubated with saturating concentrations of arachidonic acid in the Ž presence of different concentrations of metamizol . mgrml . Consistent with the common binding mode reported above, we found that the inhibition curves of cyclooxygenase-1 and cyclooxygenase-2 activity by metamizol were very similar, the IC of metamizol being about 150 50 mgrml for either cyclooxygenase-1 or cyclooxygenase-2 Ž . Fig. 2 . 
Regulation of cyclooxygenase-1 actiÕity in intact cells
To measure the capacity of metamizol to inhibit cyclooxygenase-1 and cyclooxygenase-2 activities in a more physiological context, we next decided to use different intact cell systems as a source of cyclooxygenase-1 or cyclooxygenase-2 activities. BAEC cells do not contain cyclooxygenase-2 but a constitutive cyclooxygenase-1 activity, which results in a release of prostaglandins to the Ž . extracellular medium Mitchell et al., 1994 . High concentrations of metamizol in the incubation media resulted in a We next decided to test the capacity of metamizol to inhibit cyclooxygenase-1 activity in human platelets as a model of freshly isolated intact human cells. Isolated platelets were incubated with calcium ionophore A23187 at a concentration of 0.25 mM and cyclooxygenase-1 activity was measured as thromboxane production. As shown in Fig. 3B , the IC of metamizol for cyclooxy-50 genase-1 was 486 " 56 mgrml.
Regulation of cyclooxygenase-2 actiÕity by metamizol in intact cells
Murine monocyte-macrophage J774A.1 cells have been used as a model to determine cyclooxygenase-2 activity Mitchell et al., 1994 . No prostaglandin E levels were 2 detected in the incubation media, unless cells were stimulated with lipopolysaccharide for 12 h. In these conditions, and as a result of inducing cyclooxygenase-2 expression, the concentration of prostaglandin E released to the incu- 
Determination of the IC Õalue of metamizol for 50 cyclooxygenase-2 in cell extracts
The 10-fold difference between the metamizol IC 50 values for purified cyclooxygenase-2 and in intact cells prompted us to determine the inhibitory capacity of metamizol on cyclooxygenase-2 activity, using as a source of enzyme lipopolysaccharide-activated broken murine monocyte-macrophage cells. In these conditions, metamizol inhibited prostaglandin E synthesis with a IC of 145 " 
Discussion
The discovery of an inducible isoform of cyclooxygenase allows a reinterpretation and refinement of cyclooxygenase activity inhibition, as well as an explanation of the therapeutic and side effects of NSAIDs. It is now accepted that the antiinflammatory and analgesic actions of NSAIDs are due to inhibition of cyclooxygenase-2 and the unwanted side effects such as gastric and renal toxicity are due to the inhibition of the constitutive enzyme cyclooxygenase-1. We have evaluated the ability of metamizol to inhibit cyclooxygenase-1 and cyclooxygenase-2 activities using different cyclooxygenase sources. We also propose a molecular model of the interaction between these enzymes and the main active derivative of metamizol based on automated docking calculations.
The common binding mode of 4-methylaminoantipyrine to cyclooxygenase-1 and cyclooxygenase-2 is in agreement with the data obtained with the purified enzymes showing metamizol to be equally potent in its inhibition of cyclooxygenase-1 and cyclooxygenase-2 activities, with an IC 50 of about 150 mgrml. Metamizol also has an IC of about 50 150 mgrml when tested for cyclooxygenase-2 inhibition in macrophage cell extracts. Ž . Metamizol is substantially more potent about 10-fold in inhibiting cyclooxygenase-2 activity when intact cells are used as a source of cyclooxygenase-2. The IC of 50 about 12 " 1.8 mgrml of metamizol for cyclooxygenase-2 in intact lipopolysaccharide-activated murine monocytemacrophage cells is in accordance with previous data demonstrating that the inhibition of the release of a nociceptive factor from lipopolysaccharide-activated macro-Ž phages occurs at 3.5 " 0.35 mgrml metamizol Campos et . al., 1988 . Ž . The low IC value 15-20 mgrml of metamizol for 50 cyclooxygenase-2 using intact cells as a source of cyclooxygenase-2 leads us to conclude that the analgesic effects Ž described for metamizol Brune, 1983; Matzner et al., . 1984 can be due to cyclooxygenase-2 inhibition since after drug administration the blood levels of the active Ž derivatives of metamizol are about 30 mgrml Levy et al., . 1995 . Our data also indicate that, although breaking the integrity of the cell plasma membrane should facilitate the access of metamizol to the endoplasmic reticulum and nuclear envelope, where cyclooxygenase-2 is located Ž . Morita et al., 1995 , cell purified enzymes have also been described for other Ž NSAIDs Barnett et al., 1994; Mitchell et al., 1994; . Carabaza et al., 1996 . The NSAID BF 389, for example, exhibits a 250-fold lower IC value for cyclooxygenase -2 50 in intact cells when compared with the IC obtained with 50 Ž . the purified enzyme Mitchell et al., 1994 . The reasons for these differences in the IC values depending on assay 50 conditions remain to be established. It is conceivable that the conformation of the enzyme is altered upon membrane homogenization in such a way that it loses affinity for some inhibitors or, alternatively, that binding of some inhibitors is facilitated by another cellular component present only in intact cells.
In intact cells the IC value of metamizol for cyclo-50 oxygenase-1 was more than 20-fold higher than that obtained for cyclooxygenase-2, indicating that cyclooxygenase-2 may be selectively inhibited by therapeutic concentrations of metamizol. In fact, its cyclooxygenase-2 Ž selectivity profile is superior to that of indomethacin see . Ž Section 3 or other classical NSAIDs Smith and DeWitt, . 1994; Mitchell et al., 1994; Cashman, 1996 . The IC 50 value obtained for cyclooxygenase-1 in human platelets is about 15-fold higher than the blood levels of metamizol Ž . after the administration of the drug Levy et al., 1995 . These data agree with the fact that the risk of gastrointestinal bleeding associated with metamizol use is comparable to that of paracetamol and clearly lower than that of Ž acetylsalicylic acid and other NSAIDs Laporte and Carne, . 1987; Laporte et al., 1991 . Different authors, prior to the discovery of the cyclooxygenase-2 isozyme, had proposed that the ability of metamizol to inhibit prostaglandin synthesis depends on the biological system used, providing evidence that this inhibition was particularly potent in the brain ŽDembinska- Kiec et al., 1976; Weithmann and Alpermann, . 1985; Brodgen, 1986 . The specificity of metamizol to inhibit prostaglandin synthesis in brain tissue can now be reinterpreted in the light of the selectivity shown by metamizol for cyclooxygenase-2 inhibition in intact cells. This selectivity could also underlie the pharmacological profile of this drug which is endowed with strong analgesic and antipyretic effects together with weak antiinflamatory activity.
In conclusion, in this paper we present evidence that the IC values obtained with purified enzymes or disrupted 50 cells cannot always be extrapolated to the cyclooxygenase inhibitory capacity of the NSAIDs in intact cells and probably ''in vivo''. The data presented here also indicate that metamizol does not regulate cyclooxygenase-1 activity in intact cells at therapeutic concentrations and that the inhibition of cyclooxygenase-2 achieved at these concentrations could play an important role in the analgesic effects of metamizol.
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